Table 2.
Chemokine receptor expression level frequencies, %, median (IQR)
| Response to anti-VEGF loading dose | Good | Partial | Non-response | P value* | |||
| CD14+CCR1+ | 36.9 | (19–58.8) | 21.7 | (12.3–31.5) | 63.4 | (58.2–57.2) | 0.016† |
| CD14+CCR2+ | 93.1 | (82.1–97.1) | 87.7 | (79.4–94) | 93.6 | (89.2–98.4) | 0.169 |
| CD14+CCR3+ | 0.4 | (0.2–0.6) | 0.2 | (0.2–0.4) | 0.2 | (0.2–0.3) | 0.103 |
| CD14+CCR5+ | 1 | (0.3–2.1) | 0.7 | (0.4–1.4) | 1.7 | (0.4–2) | 0.479 |
| CD14+CXCR3+ | 0.9 | (0.6–1.7) | 0.8 | (0.4–1.4) | 0.7 | (0.4–2.3) | 0.414 |
| CD14+CX3CR1+ | 35.9 | (26.1–67.3) | 40.1 | (21.3–64.1) | 24.3 | (17.3–55) | 0.500 |
| CD4+CCR1+ | 0.2 | (0.2–0.4) | 0.1 | (0–0.2) | 0.1 | (0–9.5) | 0.591 |
| CD4+CCR2+ | 5.1 | (4.1–9) | 5.1 | (3.7–6.6) | 7.2 | (6.1–8.7) | 0.479 |
| CD4+CCR3+ | 0.3 | (0.2–0.4) | 0.2 | (0.1–0.3) | 0.2 | (0.1–0.2) | 0.264 |
| CD4+CCR5+ | 2.7 | (1.2–5.3) | 1.8 | (1.1–2.5) | 4.2 | (1.9–7.9) | 0.130 |
| CD4+CXCR3+ | 2.5 | (1.6–5) | 3.2 | (1–5.1) | 2 | (1.5–3) | 0.645 |
| CD8+CCR1+ | 0.2 | (0.2–0.4) | 0.3 | (0.1–0.6) | 0.5 | (0.1–2.8) | 0.811 |
| CD8+CCR2+ | 7.8 | (4.9–12) | 7.5 | (5.7–9.2) | 7.8 | (4.7–8.7) | 0.687 |
| CD8+CCR3+ | 0.5 | (0.4–0.8) | 0.4 | (0.4–0.7) | 0.3 | (0.1–0.4) | 0.037† |
| CD8+CCR5+ | 12.6 | (4.5–23.1) | 9.4 | (4.7–14.7) | 17 | (9.6–23.9) | 0.195 |
| CD8+CXCR3+ | 4 | (1.9–6.3) | 4.2 | (1.3–8.6) | 3.3 | (1.4–9.1) | 0.978 |
*Fisher’s exact test.
†Statistically significant.